Innate Pharma S.A.
NASDAQ:IPHABiotechnology
+$0.03 today
- Market cap
- $115.05M
- Beta
- 0.89
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.54
Volume 0.50M
Average 0.07M
IPHA Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Innate Pharma S.A.NASDAQ: IPHA
Accumulated OCI · Q4 FY2025 · quarter ended Dec 2025
Accumulated OCI rises 4040.7% from a year ago
Accumulated OCI stood at €1.12M at the end of Q4 FY2025, up 4040.7% from a year earlier. Over 3 fiscal years it compounded at +10.9% a year.
Context
- Accumulated OCI amounted to 1.8% of total assets at the end of Q4 FY2025, up 1.8 pp from a year earlier.
- Accumulated OCI increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +4040.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
EUR · from the balance sheet
- Latest · FY2025
- 1.12M EUR
- Year-over-year change
- +4040.7%
- 4-year CAGR
- +25.1%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.12M | +4040.7% |
| FY2024 | 2024-12-31 | 27K | -94.5% |
| FY2023 | 2023-12-31 | 495K | -39.6% |
| FY2022 | 2022-12-31 | 819K | +79.6% |
| FY2021 | 2021-12-31 | 456K | — |
Accumulated OCI vs competitors
How IPHA compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +4040.7% is the highest of 6, against a peer median of -281.5%.
- Accumulated OCI amounts to 1.8% of total assets for IPHA, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $55.65M USD | +4.8% | +17.4% | 28.7% | |
| Dec 2025 | €1.12M EUR | +4040.7% | +10.9% | 1.8% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | CHF 0 CHF | — | — | 0.0% | |
| Mar 2026 | -$8K USD | -500.0% | — | 0.0% | |
| Mar 2026 | -$49K USD | -281.5% | — | 0.1% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | -$122K USD | +15.3% | — | 0.5% |
| Mar 2026 | -$161K USD | -600.0% | — | 0.1% | |
| Peer median (excluding IPHA) | — | -281.5% | +17.4% | 0.1% | |
Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 103.76M | 84.23M | 70.61M | 66.4M | 28.08M |
| Short-term Investments | 16.08M | 17.26M | 21.85M | 14.37M | 6.22M |
| Net Receivables | 1.66M | 3.14M | 46.49M | 1.64M | 7.61M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 11.81M | 27.88M | 0 | 0 | (4.28K) |
| Total Current Assets | 138.26M | 139.83M | 148.01M | 85.74M | 46.69M |
| Property, Plant & Equipment (Net) | 10.17M | 8.54M | 6.32M | 5.13M | 4.35M |
| Goodwill | 2K | (41M) | 0 | 0 | 0 |
| Intangible Assets | 44.19M | 42.55M | 416K | 0 | 0 |
| Long-term Investments | 39.88M | 35.12M | 9.8M | 10.28M | 10.7M |
| Tax Assets | 5.03M | 8.57M | 9.01M | 0 | 0 |
| Other Non-current Assets | 29.97M | 14.25M | 1.64M | 9.9M | 946.6K |
| Total Non-current Assets | 129.24M | 68.03M | 27.18M | 25.32M | 16M |
| Total Assets | 267.5M | 207.86M | 175.19M | 111.06M | 62.69M |
| Account Payables | 14.73M | 13.66M | 8.56M | 7.92M | 15.04M |
| Short-term Debt | 29.94M | 1.26M | 8.45M | 8.44M | 8.52M |
| Tax Payables | 7.46M | 5.98M | 7.02M | 6.96M | 0 |
| Deferred Revenue | 12.5M | 6.56M | 5.87M | 616K | 2.82M |
| Other Current Liabilities | 21.91M | 19.02M | 7.82M | 7.65M | 9.97M |
| Total Current Liabilities | 79.89M | 41.34M | 39.64M | 32.98M | 36.63M |
| Long-term Debt | 11.49M | 38.93M | 30.61M | 22.18M | 13.67M |
| Deferred Tax Liabilities | 5.03M | 8.57M | 9.01M | 0 | 0 |
| Deferred Revenue (Non-current) | 25.41M | 7.92M | 4.62M | 2.83M | 0 |
| Other Non-current Liabilities | 36.23M | 55.74M | 39.07M | 44.13M | 33.99M |
| Total Non-current Liabilities | 80.17M | 112.37M | 83.65M | 69.24M | 47.75M |
| Total Liabilities | 160.06M | 153.71M | 132.29M | 102.23M | 84.39M |
| Common Stock | 3.98M | 4.01M | 4.04M | 4.19M | 4.69M |
| Retained Earnings | (272.21M) | (330.32M) | (336.89M) | (386.36M) | (435.36M) |
| Accumulated OCI | 456K | 819K | 495K | 27K | 1.12M |
| Other Stockholders Equity | (1K) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 107.44M | 54.15M | 51.9M | 8.83M | (21.69M) |
| Total Debt | 44.25M | 42.25M | 39.89M | 31M | 22.56M |
| Net Debt | (59.51M) | (41.97M) | (30.71M) | (35.4M) | (5.52M) |
Innate Pharma S.A.
NASDAQ:IPHA
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.